IMPORTANCE Chronic fatigue syndrome (CFS) is a disabling condition with unknown disease mechanisms and few treatment options.
Low-grade systemic inflammation 13, 14 and attenuation of the hypothalamus-pituitary-adrenal axis 15, 16 have also been documented in some studies. Neuropsychological studies [17] [18] [19] suggest slight impairments of executive control functions; the details remain to be explored. One study 20 suggested that all of these features might be attributed to a persistent stress response or "sustained arousal" (Supplement [eFigure 1]). This model complies with other CFS models 21 and rests on contemporary stress theories. 22, 23 Sustained arousal might be caused by infections, 24 which seem to be precipitating factors in CFS. 25, 26 However, the precise role of microorganisms in CFS remains unclear. Clonidine hydrochloride is a centrally acting agonist to the α 2 -adrenergic receptor. 27 Clonidine inhibits sympathetic nervous activity and enhances parasympathetic nervous activity, thereby lowering heart rate and blood pressure. 28 In addition, clonidine might have anti-inflammatory properties, 29 as
well as a beneficial effect on executive functions during conditions of high arousal in primates, 30 in line with a previous CFS study. 31 The aim of the present study was 2-fold: (1) explore the pathophysiology of CFS and (2) assess the effect of low-dose clonidine treatment in adolescent CFS. We hypothesized that enhanced sympathetic activity is an important part of CFS pathophysiology and that sympatho-inhibition by clonidine would improve symptoms and function.
Methods

Patients With CFS
The Department of Paediatrics at Oslo University Hospital is a national referral center in Norway for young patients with CFS. For the present study, all 20 hospital pediatric departments in Norway, as well as primary care pediatricians and general practitioners, were invited to refer patients with CFS aged 12 to 18 years consecutively to our department. The referring units were required to confirm that the patient did not have any medical or psychiatric disorder that might explain the fatigue and that they had experienced no concurrent demanding life event.
In agreement with clinical guidelines, 2, 32 we applied a broad case definition requiring 3 months of unexplained disabling, chronic/relapsing fatigue of new onset (Supplement [eMethods] ). We did not require that patients meet any other accompanying symptom criteria.
Healthy Controls
A group of healthy adolescents with a comparable distribution of sex and age were recruited from local schools to serve as a control group for the cross-sectional comparison. Controls were not matched to cases on any variable. No chronic disease and no regular use of pharmaceutical agents were allowed.
Study Design
This study is part of the This study combined a cross-sectional and a randomized clinical design: (1) patients with CFS and healthy controls underwent a baseline investigational program at our research unit, and (2) patients with CFS were randomized to 9 weeks of treatment with oral clonidine capsules or placebo capsules in a 1:1 ratio by using a computer-based routine for stratified randomization (block size: 4) ( Figure 1) . A disease duration of 18 months (the median disease duration in a previous follow-up study 33 ) served as the stratification criterion.
The intervention part of the trial followed a modified intention-to-treat approach. 34 Pharmacy routines required randomization to be carried out at least 1 day before the study drug was dispensed to each patient. However, a separate clinical encounter to assess eligibility was not feasible. 
Investigational Program
A 1-day in-hospital assessment included clinical examination, blood sampling (antecubital venous puncture), 20°h
ead-up tilt test, and cognitive tests and always began between 7:30 AM and 9:30 AM (Supplement [eMethods]). All participants were instructed to fast overnight and abstain from tobacco products and caffeine for at least 48 hours, to bring a morning spot urine sample in a sterile container, and Copyright 2014 American Medical Association. All rights reserved.
to apply the local anesthetic lidocaine, 2.5%, and prilocaine, 2.5% (EMLA; AstraZeneca), on the skin in the antecubital area 1 hour before the blood sampling. At week 8, patients with CFS were told to postpone taking their prescribed morning dose of the study drug until after blood sampling and the head-up tilt test. All procedures were carried out in a quiet room in a fixed sequence and by the same 3 researchers (D.S., E.F., and A.W.).
After the in-hospital assessment, daily physical activity was monitored during 7 consecutive days using an accelerometer device (activPAL; PAL Technologies Ltd). In addition, a selfadministered questionnaire was completed.
Intervention
Tablets containing 25 μg of clonidine hydrochloride (Catapresan; Boehringer Ingelheim) were enclosed in orange opaque, demolition-resistant lactose capsules (Apoteket Produktion and Laboratorier). Empty capsules were used as placebo comparators.
Clonidine lowers blood pressure dose dependently, 35, 36 possibly increasing the risk of adverse effects in patients with CFS who already experience orthostatic intolerance. 9 Therefore, clonidine dosages were chosen to yield plasma concentrations within the lower range of what is considered clinically effective. Based on a previous pilot study, 37 Therapy was initiated 1 week after the baseline investigational program. One-half of the dose was given during the first 3 days to minimize introductory adverse effects. After 8 weeks of the full dose, the dose was halved for 1 additional week to avoid rebound effects, after which treatment was discontinued.
At therapy initiation, each patient was supplied with a defined number of capsules. The residual number at week 8 was counted, and an index of adherence was calculated. Clonidine plasma concentration was measured at weeks 3 and 8.
Outcomes
The primary efficacy end point was the mean number of steps 
Adverse Events
Supine and upright blood pressure and heart rate were considered the most important safety end points. A questionnaire charted the frequencies of 21 possible adverse effects of clonidine on a 1 to 5 Likert scale (ranging from never/rarely present to present all of the time) and was completed by interview at week 8. In addition, patients were routinely interviewed by telephone about adverse effects at weeks 2, 4, and 6.
Statistical Analysis
The mean (SD) number of steps per day approximates 10 000 (4000) in healthy adolescents. 38 An increment of 2500 steps per day for the CFS clonidine group was considered clinically 
Results
Study Populations
A total of 176 adolescents with CFS were referred and assessed for eligibility ( Figure 1 ). Of these, 151 fulfilled randomization criteria and 120 fulfilled the inclusion criteria (34 males and 86 females; mean age, 15.4 years), completed the investigational program, and started treatment (60 in each treatment group). Of the 120 patients, 88 individuals (73.3%) satisfied the Fukuda criteria from the International Chronic Fatigue Syndrome Study Group, 1 and 49 patients (40.8%) had depressive symptoms indicating a possible comorbid mood disorder. 40 A total of 68 healthy individuals were included as a control group (22 males 46 females; mean age, 15.1 years). Thirtynine of these adolescents completed a full investigational program, and 29 underwent only laboratory analyses.
Healthy Control Comparisons
Compared with healthy controls, patients with CFS had significantly lower number of steps per day, insomnia score, digit span backward score, and urinary cortisol to creatinine ratio. In addition, patients with CFS had higher disability score, fatigue score, average pain score, hypersensitivity score, heart rate responsiveness, and plasma norepinephrine and serum CRP concentration levels ( Table 1 ). All differences remained significant when controlling for depressive symptoms except the digit span backward score (P = .06) and serum CRP (P = .27). Supine and upright heart rates were higher in the CFS group, whereas blood pressures were similar. No significant differences were found for sex, age, body mass index, family characteristics, and blood hematology, biochemistry, and microbiology studies ( 
Intervention
Fourteen patients with CFS dropped out before week 8 (5 in the clonidine group, 9 in the placebo group), and an additional 3 withdrew prior to week 30 ( Figure 1 and Supplement [eTable 5 and eTable 6]). The mean index of adherence was 93% (clonidine group) and 92% (placebo group). At week 8 in the clonidine group, the mean plasma concentration of clonidine was 0.24 μg/L. The estimated mean steady-state concentration (trough value) was 0.23 μg/L.
Outcome
During intervention, the number of steps per day increased in the placebo group but not in the clonidine group, resulting in an estimated mean difference of −637 steps (P = .07) at week 8 ( Table 2 and Figure 2) . Plasma norepinephrine and serum CRP levels decreased in the clonidine group (mean difference, −42 pg/mL; P = .01; mean ratio, 0.69; P = .02; respectively) (to convert norepinephrine values to picomoles per liter, multiply by 5.914). No other interventional effects on efficacy variables were found. At week 8, the clonidine group had slightly but significantly lower supine and upright heart rates compared with the placebo group (P = .03 and P = .03, respectively). No other effects on cardiovascular safety end points were demonstrated. At week 30, the 2 groups were similar across all end points except for lower heart rate responsiveness in the clonidine group (P = .03). The results of per-protocol analyses were closely similar to the modified intention-to-treat analyses (Supplement [eTable 9]).
Clonidine plasma concentration was negatively associated with the number of steps per day and positively associated with the fatigue score (Supplement [eTable 10]). No other dose-response relationships were detected apart from a negative association between the estimated steady-state concentration and the insomnia score (ie, insomnia problems increased with concentrations). No differential outcome related to the 2 predefined subgroups (adherence to the Fukuda criteria and presence of depressive symptoms) was found.
Adverse Events
In the clonidine group, one patient fainted and another patient was found to have a peptic duodenal ulcer immediately after the intervention period. Sleepiness and dizziness when rising were significantly more common in the clonidine group, but there was no significant difference in the total number of self-reported adverse effects (Supplement [eTable 11]).
Discussion
There were 2 primary findings of this study. First, adolescent CFS is associated with enhanced sympathetic nervous activity, low-grade systemic inflammation, attenuated hypothalamus-pituitary-adrenal axis function, slight cognitive impairment, and large activity reduction, but not with common is consistent with a report of high plasma neuropeptide Y levels. 41 Sympathetic enhancement might result from physical deconditioning. In the present study, however, neither plasma norepinephrine level nor heart rate responsiveness was associated with the number of steps per day in patients with CFS (Supplement [eTable 12]).
In patients with CFS, lowering norepinephrine levels with clonidine was associated with lower physical activity than the activity with placebo. Thus, clonidine appeared to eliminate a relatively strong placebo effect, and the observed differences resolved when the study drug was discontinued. A recent study 42 suggested that sympathetic activation is a predictor of the placebo response.
Inflammation
Clonidine lowered both plasma norepinephrine and serum CRP levels in patients with CFS, suggesting that enhanced sympathetic nervous activity might be the cause of low-grade systemic inflammation. Catecholaminergic stimulation of lymphocytes has been shown 43 to promote secretion of the cytokine interleukin 6, which in turn enhances CRP synthesis. Alternatively, the anti-inflammatory effect of clonidine Placebo group, mean 3. Placebo group, mean 6.2 6.7
Difference (95% CI) − 0.1 (−0.6 to 0.5) −0. which suppresses the transcription factor nuclear factor κB in macrophages and thereby lowers secretion of proinflammatory cytokines. 44 Increased nuclear factor κB activity has been reported 45 in CFS.
The present study confirms findings from some studies 15, 16 of low urinary free cortisol in CFS. Systemic inflammation in CFS has been attributed to hypothalamuspituitary-adrenal axis attenuation. 13 This possibility seems less likely in light of the present results, because urinary free cortisol concentration tended to decrease during clonidine intervention. Low-grade systemic inflammation also might be caused by ongoing or reactivation of infections, but the present study does not suggest an increased presence of common microorganisms in CFS, a finding that is consistent with other reports. 46 However, our finding of elevated CRP levels in CFS might be partly explained by the coexistence of depressive symptoms, because controlling for such symptoms leveled out CRP differences between patients and controls.
Hemodynamics
Clonidine did not lower blood pressure or heart rate responsiveness and had a minimal effect on supine and upright heart rates. Furthermore, a dose-response relationship could not be demonstrated. These findings contrast with those of previous studies 35, 36 in which similar dosages and plasma concentrations of clonidine had a significant and dosedependent effect on blood pressure and heart rate. A potential plasma-expanding effect of clonidine might offset blood 
Clinical Implications
Low-dose clonidine is not clinically useful in adolescent CFS, and alternative therapeutic strategies should be explored.
The results further suggest that neither sympathetic enhancement nor low-grade systemic inflammation contributes to symptoms and disability in CFS, as postulated in the sustained arousal model. 20 The differences between the patients and the controls were small, especially for CRP levels. Sympathetic enhancement and inflammation might instead be compensatory mechanisms, because suppression of these responses in the clonidine group was associated with a poorer clinical outcome.
Strengths and Limitations
This study had good adherence and a low drop-out rate, in line with other studies in the field. 8 The wide inclusion criteria suggest generalizability to the population of adolescents with CFS referred to pediatric care. Because only 2 patients had disease duration between 3 and 6 months, the results should be generalizable to populations in which more than 6 months of fatigue is required. The single-center design and the fact that our inclusion criteria are not identical to common international standards might reduce generalizability. However, subgrouping (Fukuda criteria and comorbid depressive symptoms) did not suggest a differential response to the intervention. The results might also apply to adults with CFS because previous research does not suggest important differences in pathophysiology.
The prevalence of comorbid depressive symptoms among patients with CFS was higher than in a comparable study. 49 It is possible that we included some patients with primary depression rather than CFS; ideally, a formal psychiatric interview should have been conducted. However, a more likely explanation is low discriminant validity of the applied depression inventory, because several single items assess symptoms that are common in both depression and CFS. 40 We used a low clonidine dosage, and the study would have benefited from a more thorough pilot study of dosage algorithms. The negative effect of clonidine on physical activity and fatigue might be the result of pharmacologic effects other than sympathetic/inflammatory attenuation. Because of the multiple statistical tests used for analyses, P values close to the limit of significance (P ≤ .05) should be interpreted with caution. A, Number of steps per day: the placebo group had an increment in steps per day during the intervention period (an expected placebo effect), whereas no increment (no placebo effect) was demonstrable in the clonidine group. B, Plasma norepinephrine: the clonidine group had a stronger decrease in plasma norepinephrine compared to the placebo group. C, Serum C-reactive protein (CRP): the clonidine group had a slight decrease in CRP concentration, whereas the concentration increased in the placebo group. To convert CRP to nanomoles per liter, multiply by 9.524; norepinephrine to picomoles per liter, multiply by 5.914.
